Zoetis Inc. (NYSE:ZTS) Shares Sold by Nemes Rush Group LLC

Nemes Rush Group LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 75.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 191 shares of the company’s stock after selling 598 shares during the period. Nemes Rush Group LLC’s holdings in Zoetis were worth $33,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Magnolia Capital Advisors LLC purchased a new position in shares of Zoetis in the 2nd quarter worth $4,445,000. Creative Planning raised its holdings in shares of Zoetis by 37.5% in the 2nd quarter. Creative Planning now owns 83,231 shares of the company’s stock worth $14,429,000 after purchasing an additional 22,683 shares during the period. Copperwynd Financial LLC lifted its stake in shares of Zoetis by 33.8% in the 2nd quarter. Copperwynd Financial LLC now owns 5,005 shares of the company’s stock valued at $901,000 after purchasing an additional 1,263 shares in the last quarter. Algert Global LLC grew its holdings in shares of Zoetis by 29.5% during the 2nd quarter. Algert Global LLC now owns 1,924 shares of the company’s stock worth $334,000 after purchasing an additional 438 shares during the period. Finally, Ascent Group LLC increased its position in Zoetis by 7.9% during the 2nd quarter. Ascent Group LLC now owns 33,327 shares of the company’s stock worth $5,778,000 after purchasing an additional 2,434 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Stifel Nicolaus lifted their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $220.38.

Zoetis Trading Down 0.0 %

NYSE:ZTS opened at $194.81 on Monday. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The business’s 50-day simple moving average is $186.04 and its 200 day simple moving average is $174.78. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The stock has a market cap of $88.26 billion, a price-to-earnings ratio of 37.54, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.41 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.